118 related articles for article (PubMed ID: 37660473)
1. Modelling the influence of radiosensitivity on development of second primary cancer in out-of-field organs following proton therapy for paediatric cranial cancer.
Dell'Oro M; Wilson P; Short M; Peukert D; Bezak E
Br J Radiol; 2023 Oct; 96(1150):20230161. PubMed ID: 37660473
[TBL] [Abstract][Full Text] [Related]
2. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer.
Dell'Oro M; Short M; Wilson P; Peukert D; Hua CH; Merchant TE; Bezak E
Radiother Oncol; 2022 Jul; 172():65-75. PubMed ID: 35504365
[TBL] [Abstract][Full Text] [Related]
3. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy.
Dell'Oro M; Wilson P; Short M; Hua CH; Merchant TE; Bezak E
Med Phys; 2022 Jan; 49(1):742-755. PubMed ID: 34796509
[TBL] [Abstract][Full Text] [Related]
4. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors.
Moteabbed M; Yock TI; Paganetti H
Phys Med Biol; 2014 Jun; 59(12):2883-99. PubMed ID: 24828559
[TBL] [Abstract][Full Text] [Related]
5. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field.
Paganetti H; Athar BS; Moteabbed M; A Adams J; Schneider U; Yock TI
Phys Med Biol; 2012 Oct; 57(19):6047-61. PubMed ID: 22968191
[TBL] [Abstract][Full Text] [Related]
6. Secondary cancer risk assessments following the proton therapy of lung cancer as the functions of field characteristics and patient age.
Jia SB; Shamsabadi R
Int J Radiat Biol; 2024; 100(2):183-189. PubMed ID: 37747407
[TBL] [Abstract][Full Text] [Related]
7. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients with medulloblastoma.
Suzuki S; Kato T; Murakami M
J Radiat Res; 2021 Mar; 62(2):186-197. PubMed ID: 33341899
[TBL] [Abstract][Full Text] [Related]
8. Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning.
Geng C; Moteabbed M; Xie Y; Schuemann J; Yock T; Paganetti H
Phys Med Biol; 2016 Jan; 61(1):12-22. PubMed ID: 26605679
[TBL] [Abstract][Full Text] [Related]
9. Assessment of long-term risks of secondary cancer in paediatric patients with brain tumours after boron neutron capture therapy.
Zhang X; Geng C; Tang X; Bortolussi S; Shu D; Gong C; Han Y; Wu S
J Radiol Prot; 2019 Sep; 39(3):838-853. PubMed ID: 31195386
[TBL] [Abstract][Full Text] [Related]
10. Second malignant neoplasm risk after craniospinal irradiation in X-ray-based techniques compared to proton therapy.
Sakthivel V; Ganesh KM; McKenzie C; Boopathy R; Selvaraj J
Australas Phys Eng Sci Med; 2019 Mar; 42(1):201-209. PubMed ID: 30725439
[TBL] [Abstract][Full Text] [Related]
11. The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.
Paganetti H; Depauw N; Johnson A; Forman RB; Lau J; Jimenez R
Radiother Oncol; 2020 Aug; 149():212-218. PubMed ID: 32464163
[TBL] [Abstract][Full Text] [Related]
12. A framework for estimating radiation-related cancer risks in Japan from the 2011 Fukushima nuclear accident.
Walsh L; Zhang W; Shore RE; Auvinen A; Laurier D; Wakeford R; Jacob P; Gent N; Anspaugh LR; Schüz J; Kesminiene A; van Deventer E; Tritscher A; del Rosarion Pérez M
Radiat Res; 2014 Nov; 182(5):556-72. PubMed ID: 25251702
[TBL] [Abstract][Full Text] [Related]
13. Out-of-field doses from secondary radiation produced in proton therapy and the associated risk of radiation-induced cancer from a brain tumor treatment.
Ardenfors O; Dasu A; Lillhök J; Persson L; Gudowska I
Phys Med; 2018 Sep; 53():129-136. PubMed ID: 30241747
[TBL] [Abstract][Full Text] [Related]
14. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
15. Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients.
Tamura M; Sakurai H; Mizumoto M; Kamizawa S; Murayama S; Yamashita H; Takao S; Suzuki R; Shirato H; Ito YM
J Radiat Res; 2017 May; 58(3):363-371. PubMed ID: 27789564
[TBL] [Abstract][Full Text] [Related]
16. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
[TBL] [Abstract][Full Text] [Related]
17. Estimating the second primary cancer risk due to proton therapy compared to hybrid IMRT for left sided breast cancer.
Santos AMC; Kotsanis A; Cunningham L; Penfold SN
Acta Oncol; 2021 Mar; 60(3):300-304. PubMed ID: 33345660
[TBL] [Abstract][Full Text] [Related]
18. Risk estimation of second primary cancers after breast radiotherapy.
Santos AM; Marcu LG; Wong CM; Bezak E
Acta Oncol; 2016 Nov; 55(11):1331-1337. PubMed ID: 27379458
[TBL] [Abstract][Full Text] [Related]
19. Modelling recurrence and second cancer risks induced by proton therapy.
Manem VSK; Dhawan A
Math Med Biol; 2018 Sep; 35(3):347-361. PubMed ID: 29106564
[TBL] [Abstract][Full Text] [Related]
20. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation.
Zhang R; Howell RM; Taddei PJ; Giebeler A; Mahajan A; Newhauser WD
Radiother Oncol; 2014 Oct; 113(1):84-8. PubMed ID: 25128084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
